JP Morgan Healthcare Conference 2025: Biotech hiring trends

The 2025 JP Morgan Healthcare Conference highlighted several transformative deals in the life sciences and biotech sectors, reflecting ongoing innovation and strategic realignment. Below are the “big-ticket” transactions from the week and thoughts on their projected impact on hiring trends in 2025:

Notable transactions

1. Johnson & Johnson’s acquisition of Intra-Cellular Therapies ($14.6 billion) — expanding its mental health portfolio with Caplyta, a treatment for schizophrenia and bipolar depression. Hiring impact: increased demand for R&D and clinical expertise in mental health therapies; potential redundancies in overlapping administrative functions.

2. GSK’s acquisition of IDRx (up to $1.15 billion) — enhancing its oncology pipeline with innovative cancer treatments. Hiring impact: growth in oncology R&D roles; opportunities in clinical trials and drug development.

3. Gilead’s partnership with LEO Pharma — accelerating STAT6 inhibitor development for inflammatory diseases. Hiring impact: expansion of roles in immunology and inflammation research; possible collaboration-related workforce adjustments.

4. Eli Lilly’s acquisition of Scorpion Therapeutics’ assets (up to $2.5 billion) — strengthening precision oncology offerings through small molecule therapies. Hiring impact: demand for oncology and precision medicine expertise; likely integration of Scorpion’s talent pool through “acqui-hiring.”

5. AbbVie’s licensing agreement with Simcere Pharmaceutical (up to $1.06 billion) — broadening its haematologic oncology pipeline. Hiring impact: opportunities for specialised roles in haematologic oncology, with potential shifts in global hiring strategies.

Biotech hiring trends for 2025

1. Expansion of R&D and clinical roles: acquiring companies aim to retain and expand specialised R&D teams, with heightened demand in oncology, mental health, and inflammation, alongside growth in clinical trial management, data analytics, and regulatory affairs.

2. Organisational restructuring: mergers typically streamline support functions such as HR, finance, and operations, potentially leading to redundancies in these areas, while “acqui-hiring” strategies prioritise retaining high-value talent from startups.

3. Regional and global shifts: acquisitions involving multinational firms may lead to shifts in global hiring strategies, with increased hiring in acquiring companies’ key hubs.

4. Emerging opportunities for specialists: cross-disciplinary roles integrating AI, data science, and precision medicine are poised for growth.

5. Talent mobility: as companies restructure, professionals in overlapping roles may experience job transitions or upskilling opportunities.

Conclusion

The strategic deals from the 2025 JP Morgan Healthcare Conference underscore a dynamic period for the biotech industry. While organisational restructuring may create short-term disruptions, the increased focus on innovation, pipeline expansion, and specialised therapies points to robust demand for skilled professionals, particularly in R&D and clinical development.

With blockbuster deals and substantial Series A, B, and C fundraises emerging from the conference, the biotech industry is poised for a strong rebound in 2025.

How BioTalent can help

Navigating the evolving biotech landscape requires a partner who understands the complexities of hiring in this innovative and competitive field. At BioTalent, we specialise in connecting top-tier talent with leading organisations, ensuring you’re equipped to thrive in this dynamic environment.

Let’s shape the future of biotech together. Contact BioTalent today to discuss your hiring needs.